Establishing a leading flu vaccine player takes time, but during the two-plus years of Seqirus’ existence, the new company has worked to both hone its portfolio and boost output of next-gen cell culture flu vaccines, the chief of its parent
read moreJohnson & Johnson may have posted a loss for the fourth quarter, but it’s a necessary step toward bringing home billions in cash previously stashed overseas. More: J&J takes B hit on the way to 'immediate' tax reform windfall Source:
read moreWith drug companies discounting their products more than ever before to win better deals with payers, list prices mean less. But those discounts are likely to keep growing, analysts predict, and investors should worry about their long-term effects on the
read moreHere’s some of the other news we’re following today. More: News of Note—Pfizer, Meridian Medical Technologies, EpiPen, saline shortage Source: fierce
read moreTeva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets. More: Teva’s subcutaneous asthma drug fails in PhIII Source: News
read moreLondon, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001. More: Rexgenero wins £1.4m
read more© 1994 - 2026 B.M. Pharmaceuticals